|
|
|
Substance Name: Alectinib [USAN:INN]
RN: 1256580-46-7
UNII: LIJ4CT1Z3Y
InChIKey: KDGFLJKFZUIJMX-UHFFFAOYSA-N
Note
- An anaplastic lymphoma kinase (Alk) inhibitor.
NCI: An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.(NCI Thesaurus)
Molecular Formula
- C30-H34-N4-O2
Molecular Weight
- 482.6246
Classification Code
- Antineoplastic Agents
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Alectinib [USAN:INN]
Synonyms
- AF 802
- AF-802
- Alecensa
- Alectinib
- CH 5424802
- CH5424802
- UNII-LIJ4CT1Z3Y
Registry Numbers
CAS Registry Number
- 1256580-46-7
FDA UNII
- LIJ4CT1Z3Y
Other Registry Number
- 1416163-60-4
System Generated Number
- 1256580467